Is the degeneration of aortic valve bioprostheses similar to that of native aortic valves? Insights into valvular pathology

Expert Review of Medical Devices

Volumn 3, Issue 4, 2006, Pages 453-462

  Skowasch, Dirk ^a   Steinmetz, Martin ^a   Nickenig, Georg ^a   Bauriedel, Gerhard ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Aortic stenosis; Aortic valve bioprosthesis; Atherosclerosis; Calcification; Immunity; Inflammation; Progenitor cells

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ATHEROSCLEROSIS; BLEEDING; CALCIFICATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; ENDOCARDITIS; HEART HEMODYNAMICS; HEART VALVE BIOPROSTHESIS; HUMAN; NONHUMAN; PATHOGENESIS; POSTOPERATIVE INFECTION; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE THROMBOSIS; PREVALENCE; PROSTHESIS FAILURE; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; TISSUE REGENERATION;

AORTIC VALVE; BIOPROSTHESIS; CALCINOSIS; HEART VALVE PROSTHESIS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PROSTHESIS FAILURE; RISK FACTORS; TREATMENT OUTCOME;

EID: 33746635455     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.3.4.453     Document Type: Review

References (89)

1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease. Pathogenesis, disease progression, and treatment strategies. Circulation 111, 3316-3326 (2005).
2. Baumgartner H. Aortic stenosis: medical and surgical management. Heart 91, 1483-1488 (2005).
3. Faggiano P, Antonini-Canterin F, Erlicher A et al. Progression of aortic valve sclerosis to aortic stenosis. Am. J. Cardiol. 91, 99-101 (2003).
4. Rosenhek R, Maurer G, Baumgartner H. Should early elective surgery be performed in patients with severe but asymptomatic aortic stenosis. Eur. Heart J. 23, 1417-1421 (2002).
5. Bonow RO, Chatterjee K, de Leon AC et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease. J. Am. Coll. Cardiol. 48, e1-e148 (2006).
6. Iung B, Gohlke-Bärwolf, Tornos P et al.; on behalf of the Working Group on Valvular Heart Disease. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur. Heart J. 23, 1253-1266 (2002).
7. Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from bench to the bedside - emerging clinical and cellular concepts. Heart 89, 801-805 (2003).
8. Mohler ER III. Mechanisms of aortic valve calcification. Am. J. Cardiol. 94, 1396-1402 (2004).
9. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101, 2497-2502 (2000).
10. Otto CM, Lind BK, Kitzman DW et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med. 341, 142-147 (1999).
11. Rahimtoola SH. The year in valvular heart disease. J. Am. Coll. Cardiol. 47, 427-439 (2006).
12. Chan KL. Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol. 42, 593-599 (2003).
13. Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110, 1180-1182 (2004).
14. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesions of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90, 844-853 (1994).
15. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenquist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J. Am. Coll. Cardiol. 23, 1162-1170 (1994).
16. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 103, 1522-1528 (2001).
17. Wallby L, Janerot-Sjöberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 88, 348-351 (2002).
18. Skowasch D, Schrempf S, Lentini S et al. Presence of Chlamydia pneumoniae and cytomegalovirus in degenerated aortic valves. Z. Kardiol. 91, 290-296 (2002).
19. Skowasch D, Yeghiazaryan K, Schrempf S et al. Persistence of Chlamydia pneumoniae in degenerative aortic valve stenosis indicated by heat shock protein 60 homologues. J. Heart Valve Dis. 12, 68-75 (2003).
20. Skowasch D, Schrempf S, Wernert N et al. Cells of primarily nonvalvular origin in degenerative aortic valve stenosis and bioprostheses. Eur. Heart J. 26, 2576-2580 (2005).
21. Kuusisto J, Räsänen K, Särkioja E, Alarakkola E, Kosma VM. Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study. Heart 91, 576-582 (2005).
22. Santin M, Colombo P, Bruschi G. Interfacial biology of in-stent restenosis. Expert Rev. Med. Devices 2(4), 429-443 (2005).
23. Skowasch D, Jabs A, Andrié R, Dinkelbach S, Lüderitz B, Bauriedel G. Presence of bone-marrow- and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc. Res. 60, 684-691 (2003).
24. Bauriedel G, Jabs A, Skowasch D et al. Dendritic cells in neointima formation after rat carotid balloon injury. Coordinated expression with anti-apoptotic Bcl-2 and HSP47 in arterial repair. J. Am. Coll. Cardiol. 42, 930-938 (2003).
25. Skowasch D, Jabs A, Andrié R et al. Pathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. Tissue characteristics compared to primary atherosclerosis. J. Vasc. Res. 41, 525-534 (2004).
26. Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. Progression of aortic valve stenosis: TGF-β1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann. Thorac. Surg. 75, 457-465 (2003).
27. Kaden JJ, Dempfle CE, Grobholz R et al. Inflammatory regulation of extracellular matrix remodelling in calcific aortic valve stenosis. Cardiovasc. Pathol. 14, 80-87 (2005).
28. Kaden JJ, Dempfle CE, Grobholz R et al. Interleukin-1β promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 170, 205-211 (2003).
29. O'Brien KD, Reichenbach DD, Marcovina SM et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol. 16, 523-532 (1996).
30. Jian B, Jones PL, Quanyi L, Mohler ER III, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am. J. Pathol. 159, 321-327 (2001).
31. Satta J. Melkko J. Pollanen R et al. Progression of human aortic valve stenosis is associated with tenascin-C expression, J. Am. Coll. Cardiol. 39, 96-101 (2002).
32. Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc. Pathol. 9, 281-286 (2000).
33. Mazzone A, Epistolato MC, De Caterina R et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J. Am. Coll. Cardiol. 43, 1670-1674 (2004).
34. Galante A, Pietroiusti A, Vellini M et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J. Am. Coll. Cardiol. 38, 1078-1082 (2001).
35. Sanchez PD, Santos JL, Kaski JC et al. Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am. J. Cardiol. 97, 90-93 (2006).
36. Gerber IL, Stewart RA, Hammett CJ et al. Effect of aortic valve replacement on C-reactive protein in nonrheumatic aortic stenosis. Am. J. Cardiol. 92, 1129-1132 (2003).
37. Skowasch D, Schrempf S, Preusse CJ et al. Tissue resident C reactive protein within degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart 92, 495-498 (2006).
38. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol. 158, 1039-1051 (2001).
39. Glader CA, Birgander LS, Söderberg S et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur. Heart J. 24, 198-208 (2003).
40. Juvonen J, Laurila A, Juvonen T et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J. Am. Coll. Cardiol. 29, 1054-1059 (1997).
41. Juvonen J, Juvonen T, Laurila A et al. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann. Intern. Med. 128, 741-744 (1998).
42. Kaden JJ, Bickelhaupt S, Grobholz R et al. Pathogenetic role of Chlamydia pneumoniae in calcific aortic stenosis: immunohistochemistry study and review of the literature. J. Heart Valve Dis. 12, 447-453 (2003).
43. Radke PW, Ortlepp JR, Merkelbach-Bruse S et al. Prevalence of cytomegalovirus in nonrheumatic stenotic aortic valves. Am. J. Cardiol. 89, 477-479 (2002).
44. Rajamannan NM, Subramaniam M, Stock SR et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 91, 806-810 (2005).
45. Olsson M, Thyberg J, Nilson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol. 19, 1218-1222 (1999).
46. Sun Y, Diaz-Arias AA, Weber KT. Angiotensin-converting enzyme, bradykinin, and angiotensin II receptor binding in rat skin, tendon, and heart valves: an in vitro, quantitative autoradiographic study. J. Lab. Clin. Med. 123, 372-377 (1994).
47. O'Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106, 2224-2230 (2002).
48. Mohler ER, Adam LP, McCelland P, Graham L, Hathaway DR. Detection of osteopontin in calcified human aortic valves. Arterioscler. Thromb. Vasc. Biol. 17, 547-552 (1997).
49. O'Brien KD, Kuusisto J, Reichenbach DD et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 92, 2163-2168 (1995).
50. Kim KM. Apoptosis and calcification. Scanning Microsp. 9, 1137-1175 (1995).
51. Caira FC, Stock SR, Gleason TG et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J. Am. Coll. Cardiol. 47, 1707-1712 (2006).
52. Millonig G, Niederegger H, Rabl W et al. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler. Thromb. Vasc. Biol. 21, 503-508 (2001).
53. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005).
54. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
55. Visconti RP, Ebihara Y, LaRue AC et al. An in vivo analysis of hematopoietic stem cell potential. Hematopoietic origin of cardiac valve interstitial cells. Circ. Res. 98, 690-696 (2006).
56. Liebe V, Brueckmann M, Borggrefe M, Kaden JJ. Statin therapy of calcific aortic stenosis: hype or hope? Eur. Heart J. 27, 773-778 (2006).
57. O'Brien KD, Probstfield J, Caulfield MT et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch. Intern. Med. 165, 858-862 (2005).
58. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104, 2205-2209 (2001).
59. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J. Am. Coll. Cardiol. 40, 1723-1730 (2002).
60. Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110, 1291-1295 (2004).
61. Cowell SJ, Newby DE, Prescott RJ et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352, 2441-2443 (2005).
62. Olsen MH, Wachtell K, Bella JN et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am. J. Cardiol. 94, 1076-1080 (2004).
63. Lindblom D, Lindblom U, Qvist J, Lundstrom H. Long-term relative survival rates after heart valve replacement. J. Am. Coll. Cardiol. 15, 566-573 (1990).
64. Jamieson SW, Madani MM. The choice of valve protheses. J. Am. Coll. Cardiol. 44, 389-390 (2004).
65. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann. Thorac. Surg. 79, 1072-1080 (2005).
66. Butany J, Leask R. The failure modes of biological prosthetic heart valves. J. Long Term Eff. Med. Implants 11, 115-135 (2001).
67. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomised trial. J. Am. Coll. Cardiol. 36, 1152-1158 (2000).
68. Nollert G, Miksch J, Kreuzer E, Reichart B. Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J. Thorac. Cardiovasc. Surg. 126, 965-968 (2003).
69. Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J. Thorac. Cardiovasc. Surg. 126, 969-976 (2003).
70. Human P, Zilla P. Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration? J. Long Term Eff. Med. Implants 11, 199-220 (2001).
71. Antonini-Canterin F, Zuppiroli A, Popescu BA et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am. J. Cardiol. 92, 1479-1482 (2003).
72. Wilhelmi M, Fischer S, Mertsching H, Leyh R, Karck M, Haverich A. Is chronic graft rejection the reason for degenerative changes in allogeneic and xenogeneic heart valve prostheses: immunohistochemical evaluation of inflammatory factors. Z. Kardiol. 91, 825-832 (2002).
73. Shimizaki Y, Kuraoka S, Takeda F, Watanabe T, Inui K. Mitral valve re-replacement for impaired bioprosthesis after 19 years in a patient undergoing steroid treatment. J. Heart Valve Dis. 12, 45-47 (2003).
74. Eishi K, Ishibashi-Ueda H, Nakano K et al. Calcific degeneration of bioprosthetic aortic valves in patients receiving steroid therapy. J. Heart Valve Dis. 5, 668-672 (1996).
75. Liao K, Frater RW, LaPietra A, Ciuffo G, Llardi CF, Seifter E. Time-dependent effect of glutaraldehyde on the tendency to calcify of both autografts and xenografts. Ann. Thorac. Surg. 60(Suppl.), S343-S347 (1995).
76. Zilla P, Bezuidenhout D, Weissenstein C, van der Walt A, Human P. Diamine extension of glutaraldehyde crosslinks mitigates bioprosthetic aortic wall calcification in the sheep model. J. Biomed. Mater. Res. 56, 56-64 (2001).
77. Grabenwoger M, Sider J, Fitzal F et al. Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material. Ann. Thorac. Surg. 62, 772-777 (1996).
78. Farzaneh-Far A, Proudfoot D, Shanahan C, Weissberg PL. Vascular and valvar calcification: recent advances. Heart 85, 13-17 (2001).
79. Srivatsa SS, Harrity PJ, Maercklein PB et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J. Clin. Invest. 99, 996-1009 (1997).
80. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ. Res. 96, 717-722 (2005).
81. Shen M, Kara-Mostefa A, Chen L et al. Effect of ethanol and ether in the prevention of calcification of bioprostheses. Ann. Thorac. Surg. 71 (Suppl), S413-S416 (2001).
82. Ogle MF, Kelly SJ, Bianco RW, Levy RJ. Calcification resistance with aluminium-ethanol treated porcine aortic valve bioprostheses in juvenile sheep. Ann. Thorac. Surg. 75, 1267-1273 (2003).
83. Kim KM. Cells, rather than extracellular matrix, nucleate apatite in glutaraldehyde-treated vascular tissue. J. Biomed. Mater. Res. 59, 639-645 (2002).
84. Gao G, Wu YX, Grunkemeier GL, Furnary AP, Starr A. Durability of pericardial versus porcine aortic valves. J. Am. Coll. Cardiol. 44, 384-388 (2004).
85. Clark JN, Ogle MF, Ashworth P, Bianco RW, Levy RJ. Prevention of calcification of bioprosthetic heart valve cusp and aortic wall with ethanol and aluminium chloride. Ann. Thorac. Surg. 79, 897-904 (2005).
86. Sutherland FW, Perry TE, Yu Y et al. From stem cells to viable autologous semilunar heart valve. Circulation 111, 2783-2791 (2005).
87. Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106, 3006-3008 (2002).
88. Feldman T. Percutaneous valve repair and replacement. Challenges encountered, challenges met, challenges ahead. Circulation 113, 771-773 (2006).
89. Shemin RJ. Percutaneous valve intervention. A surgeon's perspective. Circulation 113, 774-775 (2006).